Successful Phase 3 results for Avanir migraine product

In a 275-patient Phase 3b clinical trial, Avanir Pharmaceuticals' (AVNR +1.7%) investigational migraine drug-device combination AVP-825 met its primary efficacy endpoint of achieving greater pain relief 30 minutes post dose compared to a 100 mg sumatriptan tablet. Several additional secondary endpoints were also met.

AVP-825 is a combination of low-dose sumatriptan powder (22 mg) delivered intranasally via a plastic handheld apparatus (corporate presentation, Slide 13). The user exhales into the device which propels the medication into one side of the nose where it is absorbed deep in the nasal cavity. The potential to swallow or inhale sumatriptan powder is minimized by the automatic closing of the soft palate when exhaling into the device.

Comments (3)
  • beachbliss
    , contributor
    Comments (8) | Send Message
    Supposedly large dollar potential here, and likely to be approved beginning of 2015. a third drug for avanir
    10 Jun 2014, 01:39 PM Reply Like
  • Joe McCann
    , contributor
    Comments (261) | Send Message
    This is the kind of asset that would make sense for VRX to purchase in my opinion.
    10 Jun 2014, 02:30 PM Reply Like
  • spook2b
    , contributor
    Comments (33) | Send Message
    After the close tonight, Baker Brothers filed a 13G indicating that they hold over 10.8% of AVNR shares outstanding.
    10 Jun 2014, 07:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs